Scott Applebaum
Director/Board Member at The Boys & Girls Clubs of Philadelphia
Profile
Scott Applebaum is currently the Secretary & Chief Legal Officer at VectivBio Holding AG and a Member-Governors Board at The Boys & Girls Clubs of Philadelphia.
He previously held positions such as Independent Director at Cingulate, Inc., Senior Vice President-Neuroscience Business Unit at Shire Plc, Secretary & General Counsel at Vitae Pharmaceuticals LLC, Secretary & Chief Legal Officer at Aevi Genomic Medicine, Inc., President at Context Therapeutics LLC, and Senior Counsel at Bristol-Myers Squibb SA (Switzerland).
He has also worked as the Secretary, Chief Legal & Compliance Officer at Trevena, Inc. His education includes an undergraduate degree from The Wharton School of the University of Pennsylvania and a graduate degree from Stanford Law School.
Scott Applebaum active positions
Companies | Position | Start |
---|---|---|
The Boys & Girls Clubs of Philadelphia | Director/Board Member | - |
Former positions of Scott Applebaum
Companies | Position | End |
---|---|---|
CINGULATE INC. | Director/Board Member | 2023-12-05 |
TREVENA, INC. | Compliance Officer | 2021-08-30 |
Context Therapeutics LLC
Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | President | 2019-05-31 |
VITAE PHARMACEUTICALS INC | General Counsel | 2016-11-30 |
AEVI GENOMIC MEDICINE, INC. | General Counsel | 2016-06-30 |
Training of Scott Applebaum
The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Stanford Law School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
TREVENA, INC. | Health Technology |
CINGULATE INC. | Health Technology |
Private companies | 7 |
---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Vitae Pharmaceuticals LLC
Vitae Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vitae Pharmaceuticals LLC is a clinical-stage bio-pharmaceutical company, which engages in discovering and developing novel, small molecule drugs for diseases, including chronic kidney disease, diabetes and Alzheimer's disease, and autoimmune disorders, acute coronary syndrome, and immuno-oncology. The company was founded by John J. Baldwin, Bartosz A. Grzybowski, George M. Whitesides, and Eugene Shakhnovich on May 21, 2001 and is headquartered in Fort Washington, PA. | Health Technology |
Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. Pharmaceuticals: MajorHealth Technology Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA. | Health Technology |
The Boys & Girls Clubs of Philadelphia | |
Bristol-Myers Squibb SA (Switzerland) | |
Context Therapeutics LLC
Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Context Therapeutics LLC develops novel medicines for hormone responsive cancers. The company was founded by Martin Lehr in 2016 and is headquartered in Philadelphia, PA. | Health Technology |
VectivBio Holding AG
VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Scott Applebaum